Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 31, 2024 08:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL
May 17, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 14, 2024 10:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress
May 13, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
April 24, 2024 10:00 ET | Source: Autolus Therapeutics plc

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO
April 23, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 02, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
April 01, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics Announces Changes to its Board of Directors
March 14, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 12, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right